Introduction

The EU strives to be a frontrunner in ensuring universal health coverage. In addition, it is a global leader in healthcare research and development and a major trading partner in pharmaceuticals and medical technologies. People across the EU expect to benefit from equal access to safe, state-of-the-art and affordable new and established therapies. Medicines play an important role in this regard, as they offer therapeutic options for diagnosis, treatment and prevention of diseases.

The unprecedented coronavirus pandemic (COVID-19) clearly demonstrates the need to modernise the way the EU ensures that its citizens get the medicines they need. Although this has been thrown into sharp relief by the coronavirus pandemic, it is not a new problem: even prior to the pandemic we witnessed shortages of essential medicines, such as cancer treatments, vaccines and antimicrobials. This calls for a thorough examination of how the supply chain - from the importing of active ingredients, raw materials, and medicines from third countries to internal EU production and distribution – can be made more secure and reliable.

Securing the supply of medicines is not only about existing therapies. There is also a need to ensure that the European pharmaceutical industry remains an innovator and world leader. Innovative technologies such as artificial intelligence as well as data collected from clinical experience (“real world data”) have the potential to transform therapeutic approaches and the way medicines are developed, produced, authorised and placed on the market and used. Innovation needs to be focused on areas of most need.

At the same time, more must be done to ensure that innovative and promising therapies reach all patients who need them: at present, this is not the case, with patients in smaller markets being particularly affected. Health systems, which are also seeking to ensure their financial and fiscal sustainability, need new therapies that are clinically better than existing alternatives as well as cost effective.

Finally, we are more aware than ever of the need to reduce the environmental footprint of medicines.

All these challenges will be addressed in the forthcoming EU Pharmaceutical Strategy, which should cover the whole life-cycle of pharmaceutical products from scientific discovery to authorisation and patient access.

More information on the context of the initiative, on the challenges identified so far and on the objectives can be found in the roadmap (https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12421-Pharmaceutical-Strategy-Timely-patient-access-to-affordable-medicines). Whether you are a concerned citizen or a professional in the area of medicines we would like you to let us know if you share our
objectives, what actions we should focus on and whether there are any additional aspects that we should cover.

After some introductory questions about yourself, the questionnaire continues with questions on the Pharmaceutical strategy.

When replying, please keep in mind that the questions in this survey were developed to address the long-standing issues identified in the EU pharmaceuticals system. These may be related to the problems arising from the coronavirus pandemic but are broader than that. The end of the survey includes dedicated questions on coronavirus related issues.

Please note that in this questionnaire, we do not intend to obtain data relating to identifiable persons. Therefore, in case you will describe a particular experience or situation, please do it in a way that will not allow linking to a particular individual, whether it is you or somebody else.

We thank you in advance for your time and input.

About you

• Language of my contribution
  ○ Bulgarian
  ○ Croatian
  ○ Czech
  ○ Danish
  ○ Dutch
  ○ English
  ○ Estonian
  ○ Finnish
  ○ French
  ○ Gaelic
  ○ German
  ○ Greek
  ○ Hungarian
  ○ Italian
  ○ Latvian
  ○ Lithuanian
  ○ Maltese
  ○ Polish
  ○ Portuguese
I am giving my contribution as
- Academic/research institution
- Business association
- Company/business organisation
- Consumer organisation
- EU citizen
- Environmental organisation
- Non-EU citizen
- Non-governmental organisation (NGO)
- Public authority
- Trade union
- Other

Organisation name

*Organisation name

255 character(s) maximum

European Public Health Alliance (EPHA)

Organisation size

*Organisation size

Micro (1 to 9 employees)
Small (10 to 49 employees)
Medium (50 to 249 employees)
Large (250 or more)

Transparency register number

*Transparency register number

255 character(s) maximum

Check if your organisation is on the [transparency register](#). It's a voluntary database for organisations seeking to influence EU decision-making.

18941013532-08

Which stakeholder group do you represent?
Individual member of the public
Patient or consumer organisation
Healthcare professional
Healthcare provider organisation (incl. Hospitals, pharmacies)
Healthcare pricing & reimbursement body and/or final payer
Centralised health goods procurement body
Health technology assessment body
Academic researcher
Research funder
Learned society
European research infrastructure
Other scientific organisation
Environmental organisation
Pharmaceuticals industry
Chemicals industry
Pharmaceuticals traders/wholesalers
Medical devices industry
Public authority (e.g. national ministries of health)
EU regulatory partner / EU institution
Non-EU regulator / non-EU body
Other (please specify)

Are you responding on behalf of a Small or Medium Sized Enterprise?

- Yes
- No

* First name

Yannis

* Surname

Natsis

* Email (this won't be published)

yannis.natsis@gmail.com
Country of origin

Please add your country of origin, or that of your organisation.
Belgium  Germany  Montenegro  Spain
Belize  Ghana  Montserrat  Sri Lanka
Benin  Gibraltar  Morocco  Sudan
Bermuda  Greece  Mozambique  Suriname
Bhutan  Greenland  Myanmar /Burma  Svalbard and Jan Mayen
Bolivia  Grenada  Namibia  Sweden
Bonaire Saint Eustatius and Saba  Guadeloupe  Nauru  Switzerland
Bosnia and Herzegovina  Guam  Nepal  Syria
Botswana  Guatemala  Netherlands  Taiwan
Bouvet Island  Guernsey  New Caledonia  Tajikistan
Brazil  Guinea  New Zealand  Tanzania
British Indian Ocean Territory  Guinea-Bissau  Nicaragua  Thailand
British Virgin Islands  Guyana  Niger  The Gambia
Brunei  Haiti  Nigeria  Timor-Leste
Bulgaria  Heard Island and McDonald Islands  Niue  Togo
Burkina Faso  Honduras  Norfolk Island  Tokelau
Burundi  Hong Kong  Northern Mariana Islands  Tonga
Cambodia  Hungary  North Korea  Trinidad and Tobago
Cameroon  Iceland  North Macedonia  Tunisia
Canada  India  Norway  Turkey
Cape Verde  Indonesia  Oman  Turkmenistan
Cayman Islands  Iran  Pakistan  Turks and Caicos Islands
<table>
<thead>
<tr>
<th>Country or Territory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central African Republic</td>
</tr>
<tr>
<td>Chad</td>
</tr>
<tr>
<td>Chile</td>
</tr>
<tr>
<td>China</td>
</tr>
<tr>
<td>Christmas Island</td>
</tr>
<tr>
<td>Clipperton</td>
</tr>
<tr>
<td>Cocos (Keeling) Islands</td>
</tr>
<tr>
<td>Colombia</td>
</tr>
<tr>
<td>Comoros</td>
</tr>
<tr>
<td>Congo</td>
</tr>
<tr>
<td>Cook Islands</td>
</tr>
<tr>
<td>Costa Rica</td>
</tr>
<tr>
<td>Côte d’Ivoire</td>
</tr>
<tr>
<td>Croatia</td>
</tr>
<tr>
<td>Cuba</td>
</tr>
<tr>
<td>Curaçao</td>
</tr>
<tr>
<td>Cyprus</td>
</tr>
<tr>
<td>Czechia</td>
</tr>
<tr>
<td>Democratic Republic of the Congo</td>
</tr>
<tr>
<td>Denmark</td>
</tr>
<tr>
<td>Iraq</td>
</tr>
<tr>
<td>Ireland</td>
</tr>
<tr>
<td>Isle of Man</td>
</tr>
<tr>
<td>Israel</td>
</tr>
<tr>
<td>Italy</td>
</tr>
<tr>
<td>Jamaica</td>
</tr>
<tr>
<td>Japan</td>
</tr>
<tr>
<td>Jersey</td>
</tr>
<tr>
<td>Jordan</td>
</tr>
<tr>
<td>Kazakhstan</td>
</tr>
<tr>
<td>Kenya</td>
</tr>
<tr>
<td>Kiribati</td>
</tr>
<tr>
<td>Kosovo</td>
</tr>
<tr>
<td>Kuwait</td>
</tr>
<tr>
<td>Kyrgyzstan</td>
</tr>
<tr>
<td>Laos</td>
</tr>
<tr>
<td>Latvia</td>
</tr>
<tr>
<td>Lebanon</td>
</tr>
<tr>
<td>Lesotho</td>
</tr>
<tr>
<td>Liberia</td>
</tr>
<tr>
<td>Palau</td>
</tr>
<tr>
<td>Palestine</td>
</tr>
<tr>
<td>Panama</td>
</tr>
<tr>
<td>Papua New Guinea</td>
</tr>
<tr>
<td>Paraguay</td>
</tr>
<tr>
<td>Peru</td>
</tr>
<tr>
<td>Philippines</td>
</tr>
<tr>
<td>Pitcairn Islands</td>
</tr>
<tr>
<td>Poland</td>
</tr>
<tr>
<td>Portugal</td>
</tr>
<tr>
<td>Puerto Rico</td>
</tr>
<tr>
<td>Qatar</td>
</tr>
<tr>
<td>Réunion</td>
</tr>
<tr>
<td>Romania</td>
</tr>
<tr>
<td>Russia</td>
</tr>
<tr>
<td>Rwanda</td>
</tr>
<tr>
<td>Saint Barthélemy</td>
</tr>
<tr>
<td>Saint Helena Ascension and Tristan da Cunha</td>
</tr>
<tr>
<td>Saint Kitts and Nevis</td>
</tr>
<tr>
<td>Saint Lucia</td>
</tr>
<tr>
<td>Tuvalu</td>
</tr>
<tr>
<td>Uganda</td>
</tr>
<tr>
<td>Ukraine</td>
</tr>
<tr>
<td>United Arab Emirates</td>
</tr>
<tr>
<td>United Kingdom</td>
</tr>
<tr>
<td>United States</td>
</tr>
<tr>
<td>United States Minor Outlying Islands</td>
</tr>
<tr>
<td>Uruguay</td>
</tr>
<tr>
<td>US Virgin Islands</td>
</tr>
<tr>
<td>Uzbekistan</td>
</tr>
<tr>
<td>Vanuatu</td>
</tr>
<tr>
<td>Vatican City</td>
</tr>
<tr>
<td>Venezuela</td>
</tr>
<tr>
<td>Vietnam</td>
</tr>
<tr>
<td>Wallis and Futuna</td>
</tr>
<tr>
<td>Western Sahara</td>
</tr>
<tr>
<td>Yemen</td>
</tr>
<tr>
<td>Zambia</td>
</tr>
<tr>
<td>Zimbabwe</td>
</tr>
</tbody>
</table>

*Publication privacy settings*
The Commission will publish the responses to this public consultation. You can choose whether you would like your details to be made public or to remain anonymous.

**Anonymous**

Only your type of respondent, country of origin and contribution will be published. All other personal details (name, organisation name and size, transparency register number) will not be published.

**Public**

Your personal details (name, organisation name and size, transparency register number, country of origin) will be published with your contribution.

☐ I agree with the [personal data protection provisions](#)

---

**International dependency and manufacturing**

*The EU is increasingly dependent on active ingredients originating from outside the EU. This has implications, including as regards increasing the risk of quality issues and shortages of medicines. The recent outbreak of COVID-19 shows that a disruption in the pharmaceutical products supply chain originating from outside the EU could present a major health security issue.*

1. **What type of EU action or initiative do you consider helpful to incentivise the production of active pharmaceutical ingredients for essential medicines (e.g. antibiotics, oncology medicines) in the EU?**

   *800 character(s) maximum*

   Any new incentive offered in this direction should be evaluated against the impact it will have on the price of the end products. The EU should look into existing tools which may guarantee a more diversified supply chain with more sources of API’s, excipients and semi- or finished products, irrespective of the geographical location of those sources. One such tool involves the requirements laid out when procuring medicines (for example in public tenders), whereby the concentration of production on ever fewer producers may be counteracted. Additionally, any industry claims for public support should be independently verified while any public support into this direction will have to be accounted for and factored in the final price of the product(s).

2. **What action do you consider most effective in enhancing the high quality of medicines in the EU?**

   *between 1 and 1 choices*

   ☐ Stronger enforcement of the marketing authorisation holder responsibilities
   ☐ Increased official controls in the manufacturing and distribution chain
   ☑ Other (please specify)
   ☐ I don’t know

Please elaborate your reply.
We need to: a) demand comparative effectiveness randomized clinical trials (RCTs) at the time of approval, b) require that one of the two RCTs for approval be done by an independent party, c) require superiority trials rather than inferiority trials (which is currently the standard), d) consider the duration of treatment in the assessment process, e) limit the use of surrogate endpoints (as opposed to patient-relevant endpoints which should be prioritized), f) strengthen pharmacovigilance.

Access to affordable medicines

A shortage of a medicine occurs when there are not enough medicines in a country to treat every patient with a given condition. Shortages can have a big impact on patients if their treatment is delayed because there is no alternative, or the alternative is not suited to their needs.

3. Are you concerned about medicines shortages in the EU?

- I am concerned
- I am not concerned
- I have no particular opinion

If you wish, please elaborate your reply.

Shortages is a systemic problem with diverse root causes (manufacturing difficulties, quality issues in a vulnerable distribution chain, lack of commercial interest). Amid the COVID-19 pandemic, the issue was exacerbated by extraordinary trade restrictions. Shortages have heavy consequences on patients’ health & safety: e.g. antibiotics’ shortages lead to poorer treatment options & may contribute to antibiotic resistance when treatment providers are forced to prescribe alternative antibiotics.

4. Which actions do you think would have the biggest impact on reducing shortages in the EU?

- Stronger obligations on medicines producers, and other players in the supply chain to ensure medicines are available
- Transparent information exchange among authorities on medicine stocks available in each country
- Increased cooperation among public authorities/national governments on shortages
- Multi-lingual packaging and electronic product information leaflets facilitating purchasing in different countries
- Providing incentives to companies to increase the production of medicines in the EU
Inform on and make available to patients suitable substitutes for medicines that are at risk of shortage

Other (please specify).

Please elaborate your reply.

500 character(s) maximum

Obligations for the Marketing Authorisation Holders & wholesalers to supply the market incl. non-compliance sanctions should be envisaged. The harmonization & reinforcement of notification rules across the EU will contribute to better understanding the root causes of shortages. The EU should create early warning systems and a permanent system for monitoring medicine shortages - requiring all medicines marketed in the EU to have accompanying European shortage management and prevention plans.

Innovative medicines have to undergo a centralised EU-wide marketing authorisation. Companies often initially market them in a limited number of EU countries. It can take several years before patients in the other EU countries have access to those products.

5. Do you think that companies that apply for and receive an EU-wide marketing authorisation should be required to make that product available in all EU countries?

- I agree
- I neither agree or disagree
- I disagree
- I don't know

If you wish, please elaborate your reply.

500 character(s) maximum

An effective measure to address the lack of availability of medicinal products with a centralized marketing authorization would be to oblige marketing authorization holders to place their product on the market in all EU Member States. This would require an amendment to the current EU legal framework. Such an obligation should include a deadline by which a product has to be launched in all Member States, either automatically or on request.

In recent years, there has been an increase in the number of medicines withdrawn from the market upon decisions by the manufacturers.

6. Do you have an opinion on the reasons for these market withdrawals?

- Yes
- No

If yes, please elaborate.

500 character(s) maximum
Despite the lack of transparency on what causes market withdrawals, there is a disinvestment of manufacturers in the production of old drugs & a concentration on new much more profitable products, e.g. in oncology & rare diseases. Excessive prices are driving investment shifts & the withdrawal of old but effective, widely used pharmaceutical products. Incentives, the creation of national production facilities or increasing the compounding possibilities for hospital pharmacists could be solutions.

7. Are you aware of patients not receiving the medicine they need because of its price?
   - Yes
   - No

If you wish, please elaborate your reply.
500 character(s) maximum

Yes, in the field of orphan drugs for rare diseases, cancer, cystic fibrosis and in recent years, in HCV (to name but a few). Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine (used for the prevention of ventricular tachycardia and ventricular fibrillation. The price went from approx 450 to a range from 17000 to 65000).

8. Do you think that medicine prices are justified, taking into consideration the costs associated to their development and manufacturing?
   - Yes
   - No
   - I don’t know

If you wish, please elaborate your reply.
500 character(s) maximum

Medicine prices are defined by the shareholder value, the pipeline prospects, the competition and patent landscape, the business and marketing strategies of pharmaceutical companies. Oftentimes, pharma manufacturers charge prices that “the market can bear”. In order to be justified, they should be linked to costs and have proven added therapeutic value. To this end, transparency in R&D costs is imperative.

High prices for new medicines put pressure on public health spending. The costs for research and development are not publically disclosed and there is no agreement on how to calculate such costs. In certain cases, some EU countries join forces to increase their negotiating power when discussing prices with pharmaceutical companies. Individual pricing decisions in some EU countries may affect others. As an example, some EU countries limit the prices of medicines by linking that price to average prices in other EU countries (we call this “external reference pricing”- ERP). Because of ERP, a pricing decision in one EU country can inadvertently affect the prices in others. Once patents and other forms of market protection expire, generic and biosimilar medicines can enter the market and compete with the existing ones, this also typically brings down prices. Finally, there are plans to strengthen support to EU countries to work with
each other on the clinical effectiveness of new medicines compared to existing alternatives, simply put how much better a medicine works compared to another one. This is part of the so called “health technology assessment” process.

9. What are the most effective ways the EU can help improve affordability of medicines for health systems?

   at most 3 choice(s)

   - Support the EU countries in better assessing and/or evaluating the value of medicines, meaning the effectiveness of a (new) medicine compared with existing ones
   - Help EU countries share experiences and pool expertise on pricing and procurement methods
   - Better coordination among EU countries to ensure that pricing decisions taken by one EU country do not lead to negative impacts on patient access in another EU country
   - Facilitate, market entry and a healthy market functioning for generics and biosimilars
   - More transparency on how the cost of a medicine relates to the cost of its research and development
   - There should be a fair return on public investment when public funds were used to support the research and development of medicines
   - I don't know
   - Other

Innovation in early development and authorisation

The European Commission actively supports health research and development through various funding mechanisms (e.g. Multiannual Financial Framework, Horizon 2020, Innovative Medicines Initiative partnership) and through collaborations between academia, healthcare systems and industry. Furthermore, the EU pharmaceutical legislation includes incentives to stimulate the development of innovative new medicines in areas such as paediatric and rare diseases; and market exclusivity rights to industry.

10. What actions at EU level do you consider most effective in supporting innovative research and development of medicines?

   at most 3 choice(s)

   - Make the legislative framework more adaptive to new technologies and advances in science
   - Provide more public funding for research
   - Support (including through funding) private-public partnerships
Support (including through funding) the creation of start-ups in medical research
Foster research collaboration between universities, research centres and industry
Provide research and development incentives in the form of intellectual property or market exclusivity rights for pharmaceutical companies investing in research
Simplify the requirements for the conduct of clinical trials
Other (please specify)
I don't know

Please elaborate your reply.

Public support into biomedical R&I is substantial. The public as a wise investor, not just a passive

Expected return on investment in research and development for the pharmaceutical industry depends also on the expected volume of sales; this seems to be one of the root causes of limited availability of certain medicines (e.g. medicines for rare diseases or medicines for children).

11. What do you consider are the most effective actions related to research and development of medicines in areas where there are limited or no therapeutic options (unmet needs)?

Provide market protection (protect a new medicine from competition)
Provide intellectual property protection
Provide data protection (protection of the data related to a medicine’s clinical trials)
Agree on a common understanding on what are the areas of unmet need in the EU
Funding more targeted research at EU level
Funding more targeted research at national level
Provide national schemes to support companies economically
I don’t know / no opinion
Other (please specify)
The health sector is becoming more digitised, thanks to the increased availability and collection of health data from sources such as electronic health records, patient and disease registries and mobile apps (i.e. real world data) and through the use of artificial intelligence (AI) (i.e. systems that display intelligent behaviour and the use of complex algorithms and software in the analysis of complex health data). These developments, combined with real world data are transforming health, including the discovery of medicines.

12. Which **opportunities** do you see in digital technologies (such as artificial intelligence and use of real world data) for the development and use of medicines?

600 character(s) maximum

It is up to the EMA to define the scope & questions, the regulator wishes to answer when using RWD. It should view RWD as supportive evidence or signal eliciting evidence but should be cautious using this data to establish clinical effectiveness due to high confounding. Furthermore, there needs to be a distinction between Real-world data (RWD) & real-world evidence. RWD should include pragmatic trials as in “close to everyday practice”. “Close to everyday practice” is independent of the study design, it can be done in uncontrolled (single arm) & controlled (both non-randomised or RCTs) trials.

13. Which **risks** do you see in digital technologies (such as artificial intelligence and use of real world data) for the development and use of medicines?

600 character(s) maximum

We need to refrain from framing real-world evidence as a distinct phenomenon from clinical trials. We should call observational studies for what they are; study designs that lack randomization and therefore the most important safeguard against bias. Routinely collected and available data should be used to conduct RCTs in the ‘real-world’. This would address the oft-cited criticism of randomised trials that they are not representative of actual clinical practice. By implementing trials in real-world settings, we can achieve results that are both valid and representative.

Continuous manufacturing, advanced process analytics and control, 3D printing and portable/modular systems, may revolutionise the way medicines are manufactured.

14. Are you aware of any obstacles in the EU in taking advantage of technological progress in the manufacturing of medicines?

☐ Yes
☐ No
☐ I don't know

If yes, could you please specify.

500 character(s) maximum

Personalised medicines consist of pharmaceutical and a companion diagnostic measure, whereas legislation concerns either the pharmaceutical or the diagnostic measure. Clinical use of pers med requires prescription of both and the treatment effect largely depends on the diagnosis. Differences in development and authorisation for medicines and devices make it difficult to synchronise timing. European guidelines for co-development of both and co-ordination of approval procedures should be developed.
Clinical trials are investigations in humans to discover if a new medicine is safe and effective. Clinical trials can also be used to test if a new treatment is more effective and/or safer than the standard treatment. Finally, so called “pragmatic clinical trials” can be conducted to compare the safety and effectiveness of different standard treatments in real world setting.

15. How could clinical trials in the EU be driven more by patients’ needs while keeping them robust, relevant and safe for participants?

at most 3 choice(s)

☐ By providing more national support for the conduct of so-called “pragmatic trials” with the aim to optimise treatment to patients

☐ By better coordination for larger trials comparing different treatment strategies (covering medicines and other treatments such as surgery, radiotherapy, physiotherapy)

☐ By providing support for non-commercial organisations to conduct clinical trials in fields where financial interest is weaker

☐ By involving patients’ experiences in early phases of medicine design (e.g. factor-in how the disease affects their lives and develop medicines to target symptoms that are particularly important to patients)

☐ By designing more trials that collect information on medicine tolerability or the impact of a treatment on the quality of life

☐ By taking into consideration during the design of a trial the burden of trial participation on patients’ life

☐ Other (please specify).

Certain medicines are developed based on genes, cells or tissue engineering. Some of these products are developed in hospitals. These are covered by the notion of advanced therapy medicines.

16. Is the current legal framework suitable to support the development of cell-based advanced therapy medicines in hospitals?

☐ I strongly agree

☐ I partially agree

☐ I disagree

☐ I don't know

*If you responded partially agree or disagree, please provide examples of changes that, in your view, would be required to support the development of these products.

500 character(s) maximum
EMA (CAT) has never processed a cell-based therapy developed by investigators in a hospital. Investigators/academics/clinicians have no incentives to apply for MA and do not have the required knowledge. CAT prefers to deal with professionals: SMEs and pharma. Hospitals should be incentivized to become MAH and will have to invest in skilled persons. CAT should be stimulated to deal with non-commercial parties and organize training programs.

Environmental sustainability of medicines and health challenges

Residues of several medicines have been found in surface and ground waters, soils and animal tissues across the Union. As of yet, no clear link has been established between medicine residues present in the environment and direct impacts on human health. However, the issue cannot be ignored and there is a need for a precautionary approach.

17. What actions at EU level do you consider most effective in limiting the negative environmental impact of medicines?

at most 3 choice(s)

- Cleaner manufacturing processes
- [ ] Enhanced application of the polluter pays principle
- [ ] Review the way the Environment Risk Assessment of a medicine is conducted and its consequences on the authorisation process
- [ ] Clear labelling of environmental risks to allow informed choices among equivalent therapeutic options
- [ ] Reference to environmental risks in advertising for over-the-counter medicines
- [ ] Make medicines known to pose an environmental risk available by prescription only
- [ ] Strict disposal rules for unused medicines
- [x] Prescribe medicines only when it is absolutely necessary (more prudent use)
- [ ] Medicines dispensed to patients in the quantity actually needed (e.g. number of pills, volume of solution)
- [ ] Enhanced wastewater treatment if certain residues could be better removed
- [ ] Other (please specify)

Antimicrobial resistance (AMR) is the ability of microorganisms (such as bacteria, viruses, fungi or parasites) to survive and grow in the presence of medicines. It reduces progressively the effectiveness of antimicrobials and is caused, among other things, by extensive and improper use of antimicrobial medicines. Antimicrobials include antibiotics, which are substances that fight bacterial infections. AMR can lead to problems such as difficulties to control infections, prolonged hospital stays, increased economic and
social costs, and higher risk of disease spreading. AMR is one of the most serious and urgent public health concerns.

18. Which actions do you think would have the biggest impact on fighting AMR concerning the use of medicines for patients?

*at most 3 choice(s)*

- More prudent use of antimicrobials (if necessary through restrictions on prescriptions)
- Improve the treatment of wastewater and/or manure to lower the levels of antimicrobials
- Raise citizens’ and healthcare practitioners’ awareness by informing them on appropriate use of antimicrobials and the correct disposal of unused medicines
- Introduce an obligation to use diagnostic tests before prescribing antimicrobials, for example to verify whether it is a bacterial infection before prescribing antibiotics and to define the most adequate antibiotic
- Public finance research and innovation on new antimicrobials, their alternatives and diagnostics
- Encourage public health campaigns that prevent infection through better general health including increased immunity
- Encourage public health campaigns that prevent infection through the use of vaccines
- Encourage better hygiene measures in hospitals
- Other (please specify)
- I don’t know

Innovation in antimicrobials is limited. For example, no new classes of antibiotics have been discovered for decades. Restricting the use of antibiotics to minimise the risk of developing resistance is a commercial disincentive for investment, as potential investors are concerned that their investment will not be profitable.

19. Where, in your view, should the EU focus its support for the creation of new antimicrobials or their alternatives?

*at most 2 choice(s)*

- Support academia for researching/discovering new antimicrobials or their alternatives
- Support industry for developing new antimicrobials or their alternatives
- Provide specific support to small and medium-sized enterprises (SMEs)
- Other (please specify)
New R&I models should be explored (progressive delinkage)

Health threats such as the coronavirus disease test the limits of public health systems, the pharmaceutical industry and of the pharmaceutical legislation. From the beginning of the coronavirus (COVID-19) pandemic, the EU has taken measures to coordinate a response, which includes actions ensuring the availability of medicines.

20. How has the coronavirus (COVID-19) pandemic affected you in relation to access to medicines and treatments?

Interruptions and delays in the delivery of different interventions haves compromised patient safety and the efficacy of their treatment. Patients experienced disruptions in the supply of medications (including anaesthetics and curare), discontinuation of chemotherapy and radiotherapy as well as of the operating capacity of hospitals. Access to hydroxychloroquine has been severely disrupted as well. Significant drop of seeking emergency care, eg heart attacks & strokes, was observed across the EU.

21. In your opinion and based on your experience, what can the EU do to prepare for and manage such a situation better in the future in relation to pharmaceuticals?

The pandemic points to the fact that biomedical innovation is a result of public & private investment. It demonstrates that transparency is not a nice to have but a fundamental pillar of public trust in the handling of the emergency, the safeguard of public health & the protection of patient safety. Governments should work hand in hand with the industry but not allow for blank checks. The current circumstances should not pave the way for deviations nor negative precedents (lowering of evidentiary standards, secrecy, waste of public funds etc) with lasting consequences beyond covid19.

Summary question

22. While the Commission is working on improving the EU pharmaceuticals framework, which areas of work do you find most urgent?

- Improve patients’ access to medicines
- Reduce shortages
Help national authorities ensure affordability for patients and increase health systems sustainability

Support innovation for unmet needs

Use of digitalisation to develop medicines

Help reduce anti-microbial resistance

Reduce the dependency on essential active ingredients and medicines produced outside the EU

Environmental sustainability of medicines

I don’t know

Other (please specify)

23. If you were asked before the coronavirus (COVID-19) pandemic, would you have responded differently to any of the previous questions?

☐ Yes

☒ No

☐ I don’t know

24. Is there anything else you would like to add that has not been covered in this consultation?

900 character(s) maximum

Assess the cost & impact of patent-based monopolies-exclusivities on competition, the public (health) expenditures. The correlation between corporate mergers-acquisitions across pharma, the quality of innovation & access to medicines (affordability) need to be carefully analysed. The application of patent law & rights for market exclusivity should not over-compensate companies & become barriers to access. The performance & business conduct of pharma (inputs, activity, outputs) needs to be examined. This would look at how pharma responds to health care needs, taking into account their resources & how they are used. It would contribute to more transparency in the pharma systems. The EU should strengthen pharmacovigilance to guarantee patient safety. Improve safety information for certain groups not included in clinical trials e.g. pregnant, lactation women & elderly with co-morbidities.

You may upload a position paper here.

The maximum file size is 1 MB
Only files of the type .pdf,.txt,.doc,.docx,.odt,.rtf are allowed

Contact
EU-PHARMACEUTICAL-STRATEGY@EC.EUROPA.EU